PuraPharm Past Earnings Performance

Past criteria checks 0/6

PuraPharm's earnings have been declining at an average annual rate of -0.9%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been declining at an average rate of 11.7% per year.

Key information

-0.9%

Earnings growth rate

9.8%

EPS growth rate

Pharmaceuticals Industry Growth	5.6%
Revenue growth rate	-11.7%
Return on equity	-66.8%
Net Margin	-20.8%
Last Earnings Update	30 Jun 2024

Recent past performance updates

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

Feb 06

Revenue & Expenses Breakdown

How PuraPharm makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SEHK:1498 Revenue, expenses and earnings (HKD Millions)
Date	Revenue	Earnings	G+A Expenses
30 Jun 24	419	-87	250
31 Mar 24	413	-97	258
31 Dec 23	407	-106	266
30 Sep 23	410	-112	281
30 Jun 23	412	-118	296
31 Mar 23	430	-119	311
31 Dec 22	448	-120	326
30 Sep 22	518	-147	357
30 Jun 22	588	-174	388
31 Mar 22	624	-148	397
31 Dec 21	660	-122	405
30 Sep 21	642	-45	393
30 Jun 21	624	32	380
31 Mar 21	613	32	378
31 Dec 20	602	32	375
30 Sep 20	622	-69	390
30 Jun 20	643	-171	406
31 Mar 20	669	-199	430
31 Dec 19	696	-227	455
30 Sep 19	694	-132	454
30 Jun 19	692	-38	453
31 Mar 19	719	-8	450
31 Dec 18	746	21	447
30 Sep 18	730	13	447
30 Jun 18	715	6	448
31 Mar 18	653	4	423
31 Dec 17	592	2	399
30 Sep 17	589	17	371
30 Jun 17	587	33	343
31 Mar 17	561	33	326
31 Dec 16	536	32	308
30 Sep 16	518	38	290
30 Jun 16	499	44	271
31 Mar 16	487	36	266
31 Dec 15	474	28	260
30 Sep 15	436	24	238
30 Jun 15	398	20	216
31 Mar 15	382	27	198
31 Dec 14	366	34	180
31 Dec 13	342	26	182

Quality Earnings: 1498 is currently unprofitable.

Growing Profit Margin: 1498 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 1498 is unprofitable, and losses have increased over the past 5 years at a rate of 0.9% per year.

Accelerating Growth: Unable to compare 1498's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1498 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.4%).

Return on Equity

High ROE: 1498 has a negative Return on Equity (-66.75%), as it is currently unprofitable.

PuraPharm Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

First half 2024 earnings released: HK$0.047 loss per share (vs HK$0.095 loss in 1H 2023)

PuraPharm Corporation Limited to Report First Half, 2024 Results on Aug 28, 2024

PuraPharm Corporation Limited to Report Fiscal Year 2023 Results on Mar 25, 2024

First half 2023 earnings released: HK$0.095 loss per share (vs HK$0.10 loss in 1H 2022)

PuraPharm Corporation Limited to Report First Half, 2023 Results on Aug 29, 2023

Full year 2022 earnings released: HK$0.30 loss per share (vs HK$0.31 loss in FY 2021)

Recent updates

First half 2024 earnings released: HK$0.047 loss per share (vs HK$0.095 loss in 1H 2023)

PuraPharm Corporation Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

PuraPharm Corporation Limited to Report First Half, 2024 Results on Aug 28, 2024

PuraPharm Corporation Limited has withdrawn its Follow-on Equity Offering in the amount of HKD 39 million.

PuraPharm Corporation Limited has filed a Follow-on Equity Offering in the amount of HKD 39 million.

PuraPharm Corporation Limited, Annual General Meeting, May 24, 2024

PuraPharm Corporation Limited to Report Fiscal Year 2023 Results on Mar 25, 2024

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

PuraPharm Corporation Limited Announces Cessation of Norimoto Hisayoshi as Executive Director

Is PuraPharm (HKG:1498) A Risky Investment?

First half 2023 earnings released: HK$0.095 loss per share (vs HK$0.10 loss in 1H 2022)

PuraPharm Corporation Limited to Report First Half, 2023 Results on Aug 29, 2023

Less than half of directors are independent

PuraPharm Corporation Limited Announces Appointment of Leung Stephen Kwok Keung as Non-Executive Director

Full year 2022 earnings released: HK$0.30 loss per share (vs HK$0.31 loss in FY 2021)

PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?

First half 2022 earnings released: HK$0.10 loss per share (vs HK$0.03 profit in 1H 2021)

PuraPharm Corporation Limited to Report First Half, 2022 Results on Aug 27, 2022

Purapharm Corporation Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Founder recently bought HK$118k worth of stock

Less than half of directors are independent

Purapharm Corporation Limited Announces Retirement of Non-Executive Director

Full year 2021 earnings released: HK$0.31 loss per share (vs HK$0.086 profit in FY 2020)

PuraPharm Corporation Limited, Annual General Meeting, May 23, 2022

PuraPharm Corporation Limited, Annual General Meeting, May 23, 2022

PuraPharm Corporation Limited Provides Earnings Guidance for the Year Ending December 31, 2021

Investor sentiment improved over the past week

Founder recently bought HK$86k worth of stock

First half 2021 earnings released: EPS HK$0.03 (vs HK$0.033 in 1H 2020)

Is PuraPharm (HKG:1498) A Risky Investment?

First half 2021 earnings released: EPS HK$0.03 (vs HK$0.033 in 1H 2020)

CFO & Company Secretary Ka Kuen Lau has left the company

Independent Non-Executive Director Kin Keung Chan has left the company

Executive Vice-Chairman Kam Biu Tsoi has left the company

Non-Executive Director Kin Man Chan has left the company

Full year 2020 earnings released: EPS HK$0.086 (vs HK$0.87 loss in FY 2019)

PuraPharm's (HKG:1498) Profits Appear To Have Quality Issues

Full year 2020 earnings released: EPS HK$0.086 (vs HK$0.87 loss in FY 2019)

PuraPharm Corporation Limited to Report Fiscal Year 2020 Results on Mar 25, 2021

New 90-day high: HK$0.80

New 90-day high: HK$0.78

Founder recently bought HK$54k worth of stock

New 90-day low: HK$0.66

How Much Is PuraPharm Corporation Limited (HKG:1498) Paying Its CEO?

PuraPharm Corporation Limited Appoints Norimoto Hisayoshi as Executive Director, Effect from 17 November 2020

First half earnings released

Founder recently sold HK$9.5m worth of stock

New 90-day high - HK$0.80

Earnings released

PuraPharm Corporation Limited to Report First Half, 2020 Results on Aug 25, 2020

New 90-day low - HK$0.60

Revenue & Expenses Breakdown

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies